January 26, 2018January 26, 2018

Phase 1 Trial Results Support Powder Formulation of Treprostinil Advancing to Phase 3 Studies, Liquidia Says

News, PAH News

Results of a Phase 1 clinical trial of Liquidia Technologies’ powder formulation of treprostinil for pulmonary hypertension were promising enough to advance it into Phase 3 trials, the company reports. ... Read more

January 9, 2018January 9, 2018

Liquidia Starts Phase 3 Clinical Trial of Pulmonary Hypertension Treatment

News, PAH News

Liquidia Technologies has started a Phase 3 clinical trial to evaluate LIQ861 as a treatment for pulmonary arterial hypertension. LIQ861 is a dry-powder, inhaled formulation of treprostinil that Liquidia developed to ... Read more

Pin It on Pinterest